about
Granaticins and their biosynthetic gene cluster from Streptomyces vietnamensis: evidence of horizontal gene transfer.Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.Ethyl 4-anilino-2,6-bis-(4-fluoro-phen-yl)-1-phenyl-1,2,5,6-tetra-hydro-pyridine-3-carboxyl-ate.Methyl 4-(4-fluoro-anilino)-1,2,6-tris-(4-fluoro-phen-yl)-1,2,5,6-tetra-hydro-pyri-dine-3-carboxyl-ateEthyl 2,6-bis-(4-chloro-phen-yl)-4-(4-fluoro-anilino)-1-(4-fluoro-phen-yl)-1,2,5,6-tetra-hydro-pyridine-3-carboxyl-atePolyisoprenylated methylated protein methyl esterase overexpression and hyperactivity promotes lung cancer progression.Mechanisms of Chromosome Congression during Mitosis.Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.In vitro pathological modelling using patient-specific induced pluripotent stem cells: the case of progeria.Protein farnesylation and disease.Computational enzymatic catalysis--clarifying enzymatic mechanisms with the help of computers.Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis.Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation.Metabolic Labeling with an Alkyne-modified Isoprenoid Analog Facilitates Imaging and Quantification of the Prenylome in Cells.Trinuclear Metal Clusters in Catalysis by Terpenoid Synthases.Molecular Approaches To Target GPCRs in Cancer Therapy.Small-Molecule Modulation of Lipid-Dependent Cellular Processes against Cancer: Fats on the GunpointMolecular dynamics analysis of a series of 22 potential farnesyltransferase substrates containing a CaaX-motif
P2860
Q34197910-62F309BE-211D-4D46-82EB-15403993454FQ36159154-0FE6283B-30F1-4042-A1CA-03929BA56EB7Q36602632-ED892360-2B3F-4D62-8394-1C432BA1F594Q36657211-C5043F90-D00F-4FFF-A0DD-6105747B9FA9Q36775649-3BF4AA3F-EEEC-4EC9-8AA1-C7137CC31774Q37650129-50586558-77F0-4AD2-9AA6-EAA1E81690A7Q37728193-93CCAD96-977E-4353-888B-C5A2E73FDCDFQ37733593-B90C10E3-DA8D-42B2-AD4A-D36D88BFCB30Q37958975-D8C68A77-61B4-485F-8BB1-A53AA21A6AC6Q37981563-F0088345-602F-4E6A-8051-E71FC45316E6Q38032573-B1634F17-5910-418D-897D-79C7FFA6E34DQ39074628-1E423C00-DCF9-4017-849C-B94EFC78B9F0Q40181069-1369C353-3DF3-45CA-AAD1-F493D3E04DBEQ41535966-2407A6DC-3361-4231-882C-2EB1EF30D7E8Q42729229-5B49AE50-A51E-467D-A642-A7FE4353E7EBQ46850333-BE063E8A-12C0-404E-9B17-7A356999A170Q57169171-C6508243-4E71-4E58-B47C-589C244A167AQ57990991-672E5A18-62D9-48EB-BE96-996DA8D8F78C
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Farnesyltransferase inhibitor as anticancer agent
@ast
Farnesyltransferase inhibitor as anticancer agent
@en
Farnesyltransferase inhibitor as anticancer agent
@nl
type
label
Farnesyltransferase inhibitor as anticancer agent
@ast
Farnesyltransferase inhibitor as anticancer agent
@en
Farnesyltransferase inhibitor as anticancer agent
@nl
prefLabel
Farnesyltransferase inhibitor as anticancer agent
@ast
Farnesyltransferase inhibitor as anticancer agent
@en
Farnesyltransferase inhibitor as anticancer agent
@nl
P1476
Farnesyltransferase inhibitor as anticancer agent
@en
P2093
Anuj G Agrawal
Rakesh R Somani
P304
P356
10.2174/138955709788452702
P407
P577
2009-06-01T00:00:00Z